FDA QMSR and ISO 13485 in SEA: How Silcotech Industry Resolves the Medical Supplier Qualification Challenge
Published on 28th Sept 2026
FDA QMSR and ISO 13485 in SEA: How Silcotech Industry Resolves the Medical Supplier Qualification Challenge
The US Food and Drug Administration's Quality Management System Regulation (QMSR) took effect on 2 February 2026, amending 21 CFR Part 820 and incorporating ISO 13485:2016 by reference. In Southeast Asia, the timing matters. Malaysia's medical-device exports reached RM34.54 billion in 2025, supported by strengths in precision engineering, plastics and rubber, packaging and sterilisation, and many of those exports depend on components that carry US regulatory expectations with them.
The supplier qualification reality, however, is more complicated than "the FDA now uses ISO 13485".
A medical elastomer component looks like one of the simplest parts in a device. In practice, a single silicone seal, grommet or catheter tip depends on the compound and its durometer, the cure profile, the mould's venting, the tolerance against a mating part, the cleanliness of the moulding environment, and the documentation that follows it into the OEM's audit file. Each of those has its own qualification cycle. A shortfall in any one of them can surface as a leak, a failed audit or a field complaint months after the part shipped.
The core problem: the QMSR makes ISO 13485 a shared language between OEMs and suppliers, but it does not make every certified supplier suitable for every programme. Certified scope, process control and record quality still differ from site to site, and the OEM still has to prove it. A mismatch surfaces late, as a re-qualification, a delayed submission or an inspection observation.
Silcotech Industry is a precision liquid silicone rubber (LSR) and elastomer manufacturer in Sungai Petani, Kedah, Malaysia, supplying since 2006 under ISO 9001 and ISO 13485 certified quality management. This article explains what the QMSR changes for supplier qualification, what a capable medical elastomer manufacturer should be able to show, and how an integrated model reduces the risk for OEMs.
The Supplier Qualification Problem in SEA
A certificate is an entry point, not a conclusion
ISO 13485 certification tells an OEM that a supplier operates a documented medical-device quality system. It does not say whether the certified scope covers the proposed site, the proposed process or the proposed material. It also does not tell the OEM how the system behaves under pressure: when a material lot is substituted, when a mould is repaired, or when a customer complaint traces back to a cure deviation.
Regulators take the same view. Commentary on the QMSR notes that certification by other parties does not exempt a facility from an FDA inspection. For an OEM, the certificate opens the conversation. Evidence closes it.
What the QMSR changed, and what it left in place
The QMSR does not copy ISO 13485 into US law line by line. Most of Part 820 now points to the relevant ISO clause, while a small number of sections remain because FDA concluded ISO 13485 did not fully cover them. The table below summarises the shifts that matter most to a supplier relationship.
| Area | What changed or remains | Consequence for the OEM |
|---|---|---|
| Structure of Part 820 | Most requirements now refer to ISO 13485:2016 clauses | OEM and supplier quality systems share one reference framework |
| Record terminology | Device master record, design history file and device history record give way to the medical device file and design and development file | Supplier records need to map cleanly to the OEM's file structure |
| Labelling and packaging | A new section 820.45 covers labelling and packaging controls | Packing and identification steps need explicit, auditable control |
| Inspection approach | FDA stopped using QSIT and adopted Compliance Program 7382.850 on 2 February 2026 | Inspections follow a new method, so supplier records must stand up to it |
| Certification status | ISO 13485 certification does not replace FDA inspection | Supplier evidence must be available to the OEM, not just certified |
The table shows a framework that has converged, not a rulebook that has disappeared. The FDA-specific overlay still applies, and the legal manufacturer still carries responsibility for it. What changes is how directly supplier evidence feeds the OEM's own file.
Elastomer components hide their risk in the process
The third difficulty is specific to silicone and rubber. A moulded elastomer part is difficult to verify by inspection alone. Compression set, cure completeness and surface cleanliness are largely determined upstream, in the compound, the mould and the process window. That is why supplier controls matter more here than on a machined metal part: the quality of the part is the quality of the process that made it.
For medical elastomers, the risk sits in the process, not the finished part.
Why Malaysia Is the Right Manufacturing Base for Medical Elastomer Components
Malaysia already holds an established position in global healthcare supply chains. The government's own framing of the sector points to capability across electronics, precision engineering, plastics and rubber, packaging and sterilisation, which are the disciplines a medical elastomer programme draws on.
Structural Advantages
- A working medical-device ecosystem. Rubber, plastics, packaging and sterilisation capability sit within one national supply base, which shortens the loop between component, assembly and finishing.
- Regulatory familiarity. Malaysian manufacturers already work to international medical standards, and domestic medical-device registration exists alongside export requirements.
- Northern corridor logistics. Kedah's position within the northern industrial corridor gives access to established electronics and medical manufacturing clusters.
- Regional diversification. Sourcing from Malaysia allows OEMs to spread supply-chain exposure beyond a single region without lowering quality expectations.
Key insight: the value of a Malaysian base is not lower cost alone. It is a supplier ecosystem in which materials, cleanroom moulding and downstream finishing can be qualified together.
How Silcotech Industry Supports Medical Elastomer Programmes
For a medical component, integration is an engineering requirement. Material selection affects cure behaviour, cure behaviour affects dimensional stability, and dimensional stability affects whether a seal performs against its mating housing. When those decisions sit with different suppliers, no one owns the interaction between them.
Silcotech Industry carries a programme from material formulation and tooling design through to mass production, with in-house R&D and tooling. Its medical grade rubber products are described as compliant with FDA, USP and ISO standards.
End-to-End Manufacturing for Medical Components
The table below shows how each stage of a medical elastomer programme maps to a Silcotech Industry capability.
| Process stage | Silcotech Industry capability | What it means for the OEM |
|---|---|---|
| Design review | DFM and tool technology evaluation, including mould-filling simulation | Manufacturability issues found before tooling spend |
| Tooling | In-house tooling design and prototyping | One team owns the mould and the part it produces |
| Moulding | LSR injection, extrusion and compression moulding, tolerances of 0.08 mm to 0.15 mm | Repeatable geometry on seals, gaskets and complex parts |
| Controlled environment | Class 8 and Class 9 cleanrooms with air filtration and personnel protocols | Low-particulate, low-outgassing production for medical use |
| Compliance support | Compliance testing and certification services | Test evidence produced alongside the part, not after it |
| Scale-up | Quick-turn samples through low to high volume | Same team from prototype to repeat production |
The table shows the stages. The paragraph that matters is what happens between them. Medical quality failures rarely come from one bad part. They come from handoffs: a tooling change that is not reflected in a process record, a material substitution that reaches the floor before the OEM has reviewed it, a cleanroom excursion that is logged but never linked to the affected lots. When design, tooling, moulding and cleanroom production sit under one roof, root-cause work follows one thread instead of four.
Silcotech Industry's cleanroom page states control of temperature to ±1°F, humidity to ±2% and particle control below 0.1 μm. These are the company's stated control figures, and OEMs should confirm the monitoring and record-keeping behind them during audit. [VERIFY: current cleanroom monitoring frequency and the records available to customers]
Handling the Regulated, High-Mix Reality
Medical programmes are rarely uniform. A supplier may carry catheter components, wearable-device buttons and diagnostic seals at the same time, each with different material and documentation needs. Silcotech Industry manages this through:
- Programme-specific material qualification rather than a single default compound
- Documented process windows agreed during DFM and confirmed at sampling
- Cleanroom production for components where particulate and outgassing control matter
- Quick-turn soft tooling and samples for early design iterations before hard tooling is committed
How Silcotech Industry Helps OEMs Meet QMSR Supplier Expectations
Supplier readiness is designed in before an audit, not assembled after it. The seven areas below are the ones OEM quality teams most often examine. For each, Silcotech Industry's integrated approach gives the OEM a single point of accountability.
Document control and change control
Drawings, specifications, work instructions and test procedures need controlled revisions, and any change to a material, process, supplier, tool or site should be reviewed before it reaches production. Because tooling and moulding are managed within Silcotech Industry, a mould change and its process consequences can be assessed together. [VERIFY: Silcotech Industry's customer change-notification procedure and lead times]
Traceability and production records
An OEM should be able to follow a finished unit back to its material lot, moulding run and inspection results. Records that support audits, investigations and post-market activity are the practical proof that the quality system works. [VERIFY: lot traceability method, batch record contents and retention period]
Non-conformance, CAPA and supplier controls
A credible CAPA process identifies root cause and verifies that the fix held. OEMs should ask to see a recent example, not only the procedure. They should also ask how approved material sources are controlled and how substitutions are handled.
Operational reality: the strongest evidence in a supplier audit is a recent, real record: a closed CAPA, a change-control file, a traceability pull. Procedures show intent; records show operation.
Questions to Ask Before Adding a Supplier to Your Approved List
The following questions turn the QMSR shift into a practical prequalification check.
- Is the ISO 13485 certificate current, and does its scope cover the proposed site and processes?
- How are engineering changes, material substitutions and supplier changes controlled?
- Can a finished unit be traced to its material lot, inspection results and production records?
- How are deviations, non-conforming material and corrective actions managed?
- What validation, testing and quality records are available for this programme?
- Which processes run in-house and which go to subcontractors?
- If controlled-environment work is needed, what cleanroom classification, monitoring and process controls apply?
Silcotech Industry welcomes these questions early, ideally during DFM, when answers can still shape the design.
Medical Applications Silcotech Industry Supports
Fluid control and diagnostics
Fluid-path components need clean surfaces, tight tolerances and stable seal behaviour. Silcotech Industry's cleanroom page lists catheter tips, seals, housings and grommets for fluid control and diagnostic devices.
- Catheter tips
- Seals and gaskets for fluid paths
- Housings and grommets for diagnostic devices
Implantable and catheter-delivered components
Biocompatibility and precise film thickness dominate here. A Silcotech Industry case study describes a catheter-deployable cardiac occluder, using a silicone film of 0.08 mm ±10% overmoulded onto a nitinol wire mesh and reinforced with polyester fabric.
- Implantable elastomer components with biocompatibility requirements
- Overmoulded silicone films on wire or fabric structures
Wearable and monitoring devices
Skin contact, repeated flexing and cleanliness all matter. The cleanroom page includes overmoulded elastomer switch buttons for wearable monitoring devices.
- Overmoulded switch buttons
- Silicone housings and seals for wearable electronics
Skin-contact and wound care products
Silcotech Industry's silicone wound care patch case study covers a reusable medical-grade patch for scar care, involving silicone casting, breathable-layer lamination and adhesion control, registered with Malaysia's Medical Device Authority.
- Reusable silicone patches
- Laminated silicone products with controlled adhesion
The Integration Advantage for Quality and Speed
A fragmented supply model asks the OEM to be the integrator. Every handoff between vendors is a place where a record can be lost, a change can go unreported, or a specification can be interpreted differently. The comparison below sets that model against Silcotech Industry's integrated approach.
| Risk in a fragmented model | Silcotech Industry's integrated approach | Result for the OEM |
|---|---|---|
| Design, tooling and moulding specified separately | DFM, tooling and moulding managed together | Fewer re-spins and clearer accountability |
| Changes made at one vendor, unseen by the next | Tooling and process changes assessed in one place | Change impact understood before production |
| Cleanliness controlled by a separate finisher | Cleanroom moulding under the same quality system | Contamination risk addressed at source |
| Records held across several suppliers | Process and inspection records from one site | Simpler audit trail and evidence file |
| Root-cause work split across vendors | One team investigates the full process | Faster corrective action |
The practical outcome is a shorter NPI cycle, fewer late surprises and faster yield stability. The QMSR raises the value of that simplicity, because the OEM's evidence chain is only as strong as its weakest supplier record. For related reading on how small components create large product risk, see Is a small rubber component causing your biggest product problem?
Partnering with Silcotech Industry for Medical Elastomer Manufacturing in SEA
The QMSR opens a clearer path between international ISO 13485 practice and US expectations. The structural challenge remains: OEMs still need suppliers whose certified scope, process control and records match the product in front of them. Silcotech Industry offers:
- ISO 9001 and ISO 13485 certified quality management. A documented quality system to build supplier qualification on.
- Class 8 and Class 9 cleanroom manufacturing. Controlled-environment production for medical components.
- Integrated DFM, tooling and moulding. One team accountable from drawing to repeat production.
- Precision LSR processing. Tolerances of 0.08 mm to 0.15 mm on complex parts.
- Quick-turn prototyping through volume production. A single supplier from first sample to scale.
The question is not whether QMSR expectations reach the supply chain. It is whether the OEM absorbs the qualification risk alone, or shares it with a manufacturer built to document and control it.
To discuss a medical elastomer programme, contact Silcotech Industry.